Clinical trial
Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
NCT00402012 is registered in ClinicalTrials.gov with Pennington Biomedical Research Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
- Lead sponsor
- Pennington Biomedical Research Center
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- December 31, 2007
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.